Hyperfibrinolysis during liver transplantation is associated with bleeding

Thrombosis and Haemostasis

Volumn 113, Issue 5, 2015, Pages 1145-1148

  Roullet, Stéphanie ^a   Freyburger, Geneviève ^a   Labrouche, Sylvie ^a   Morisse, Eloïse ^a   Stecken, Laurent ^a   Quinart, Alice ^a   Laurent, Christophe ^a   Sztark, François ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; SERPINE1 PROTEIN, HUMAN;

ACUTE LIVER FAILURE; ADULT; ALCOHOL LIVER CIRRHOSIS; AMYLOIDOSIS; BLEEDING; BLOOD CLOTTING DISORDER; CHRONIC HEPATITIS C; EUGLOBULIN LYSIS TEST; FEMALE; HUMAN; HYPERFIBRINOLYSIS; LETTER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPERATIVE BLOOD LOSS; PRIORITY JOURNAL; ADVERSE EFFECTS; ANOXIA; COMPLICATION; FIBRINOLYSIS; LIVER FAILURE; METABOLISM; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR;

ANOXIA; FEMALE; FIBRINOLYSIS; HEMORRHAGE; HEPATECTOMY; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84931265037     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-08-0655     Document Type: Letter

References (32)

1. Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888–896.
2. Dzik WH, Arkin CF, Jenkins RL, et al. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood 1988; 71: 1090–1095.
3. Segal HC, Hunt BJ, Cottam S, et al. Changes in the contact system during orthotopic liver transplantation with and without aprotinin. Transplantation 1995; 59: 366–370.
4. Lisman T, Leebeek FWG, Mosnier LO, et al. Thrombin-Activatable Fibrinolysis Inhibitor Defi-ciency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. Gastroenterology 2001; 121: 131–139.
5. Rijken DC, Kock EL, Guimarães AHC, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116–2122.
6. Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230–237.
7. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553–558.
8. Wang Y, Liu Y, Han R, et al. Hemostatic variation during perioperative period of orthotopic liver transplantation without venovenous bypass. Thromb Res 2008; 122: 161–166.
9. Roullet S, Pillot J, Freyburger G, et al. Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation. Br J Anaesth 2010; 104: 422–428.
10. Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Prog Chem Fibrinolysis Thrombolysis, vol 2. New York: Ravens Press; 1976. pp. 57–65.
11. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792–797.
12. Surawong A, Rojnuckarin P, Juntiang J, et al. Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients. Asian Biomed 2010; 4: 199–206.
13. Sié P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anaesth 2006; 53: S12–20.
14. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427–436.
15. Eriksson E, Ranby M, Gyzander E, et al. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91–101.
16. Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220–225.
17. Bos R, Hoegee-de Nobel E, Laterveer R, et al. A one-step enzyme immunoassay for the determination of total tissue-type plasminogen activator (t-PA) antigen in plasma. Blood Coagul Fibrinolysis 1992; 3: 303–307.
18. Brogren H, Wallmark K, Deinum J, et al. Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1. PLoS ONE 2011; 6: e26762.
19. Segal H, Cottam S, Potter D, et al. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25: 683–688.
20. Porte RJ, Bontempo FA, Knot EA, et al. Tissuetype-plasminogen-activator-associated fibrinolysis in orthotopic liver transplantation. Transpl Proc 1989; 21: 3542.
21. Pereboom IT, Adelmeijer J, van Leeuwen Y, et al. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transpl 2009; 9: 1189–1196.
22. Segal HC, Hunt BJ, Cottam S, et al. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin. Transplantation 1994; 58: 1356–1360.
23. Hunt BJ, Cottam S, Segal H, et al. Inhibition by aprotinin of tPA-mediated fibrinolysis during orthotopic liver transplantation. Lancet 1990; 336: 381.
24. Mimuro J, Mizuta K, Kawano Y, et al. Impact of acute cellular rejection on coagulation and fibrinolysis biomarkers within the immediate post-operative period in pediatric liver transplantation. Pediatr Transpl 2010; 14: 369–376.
25. Kluft C. Constitutive synthesis of tissue type plasminogen activator and plasminogen activator inhibitor type 1: conditions and therapeutic targets. Fibrinolysis 1994; 8 (Suppl 2): 1–7.
26. Porte RJ, Bontempo FA, Knot EA, et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47: 978–984.
27. Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009; 13: 21–31.
28. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: Lessons from the liver. Thromb Haemost 2008; 100: 992–1006.
29. Schofield N, Sugavanam A, Thompson K, et al. No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin. Liver Transpl 2014; 20: 584–590.
30. Steib A, Gengenwin N, Freys G, et al. Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. Br J Anaesth 1994; 73: 645–648.
31. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46: 727–733.
32. Tripodi A, Mannucci PM. The Coagulopathy of Chronic Liver Disease. N Engl J Med 2011; 365: 147–156.